Optimizing drug combinations to treat tuberculosis effectively
Lesion-centric optimization of multidrug therapies for tuberculosis
This study is looking for the best combinations of antibiotics to treat tuberculosis more effectively, especially for those with drug-resistant strains, by testing them in lab models that mimic real TB infections, so patients can have shorter treatments and a lower chance of getting sick again.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts University Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10755301 on NIH RePORTER |
What this research studies
This research focuses on improving the treatment of tuberculosis (TB) by finding the best combinations of multiple antibiotics to effectively target the diverse bacterial populations present in TB lesions. The approach involves developing advanced laboratory models that mimic human TB lesions, allowing researchers to test various drug combinations more accurately than traditional methods. By using high-throughput techniques, the study aims to identify the most effective drug regimens that can shorten treatment duration and reduce the risk of relapse in patients. This research is particularly important as it addresses the challenges posed by drug-resistant strains of TB.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with tuberculosis, especially those with drug-resistant forms of the disease.
Not a fit: Patients with non-tuberculosis infections or those who do not have access to the required treatment facilities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and shorter treatment options for tuberculosis patients, potentially reducing the duration of therapy and improving outcomes.
How similar studies have performed: Previous research has shown promise in optimizing drug combinations for other infectious diseases, indicating that this approach could be effective for tuberculosis as well.
Where this research is happening
Boston, United States
- Tufts University Boston — Boston, United States (Active)
Researchers
- Principal investigator: Aldridge, Bree Beardsley — Tufts University Boston
- Study coordinator: Aldridge, Bree Beardsley
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.